Cytiva Belgium BV

PD is marked by the degeneration of dopamine-producing neurons. Credit: Myibean/Shutterstock. SmartCella has secured exclusive rights to advance research into cell replacement therapies for the treatment of Parkinson’s disease (PD). The agreement with Karolinska Institutet’s Department of Cell and Molecular Biology professor Johan Ericson could propel the research into clinical development and commercialisation. SmartCella CEO Niklas Prager stated: “The agreement with Johan Ericson is an important addition to our project pipeline within regenerative medicine. Johan’s research around dopamine-producing neurons shows a clear improvement compared to existing methods. “By combining Johan’s protocol, which has better results and efficacy, with our GMP [good manufacturing practice] manufacturing and process development capabilities we will have an advantage in bridging the gap between labs and clinics.” Along with Dr Zjanna Alekseenko of the Karolinska Institutet, Ericson developed a new pluripotent stem cell-based technology that significantly enhances the yield of therapeutic mesencephalic dopamine (mDA) neurons post-transplantation. The technology also minimises the presence of undesired and potentially harmful cells, leading to transplants enriched for mDA neurons. These neurons exhibit the hallmark characteristics of gold-standard endogenous neurons. Preclinical transplantation studies revealed that grafted cell preparations showed therapeutic performance, indicating a best-in-class potential for the cell product. Ericson stated: “The pre-clinical results we have so far are truly encouraging and we are confident that our translational approach holds great promise for the establishment of a competitive and therapeutically high-effective cell product to treat Parkinson’s disease in the future. “We have also adapted the cell manufacturing process into a scaleable format with xeno-free materials, and with the process development, scale-up capabilities and knowledge of SmartCella, we will be able to accelerate the path towards clinical studies in humans.” PD, which affects ten million individuals across the globe, is marked by the degeneration of dopamine-producing neurons. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva . Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content. Free Whitepaper Cell and gene therapies: Pipe dream to pipeline The cell and gene industry is gaining momentum, with a new wave of therapies promising to transform the way doctors treat, and even cure, disease. In this report, Cytiva and GlobalData have collaborated to explore the rise of the cell and gene therapy industries, the current state of the market, present and future opportunities for advancement, and the challenges that lie ahead. Thank you. You will receive an email shortly. Please check your inbox to download the Whitepaper. By Cytiva Thematic By downloading this Whitepaper, you acknowledge that GlobalData may share your information with Cytiva Thematic and that your personal data will be used as described in their Privacy Policy

为促进科研专家学者的交流与合作，拓展跨学科的圈层与互动，共同探讨科研领域的最新进展，由复旦大学校友总会光华生命健康分会与Cytiva思拓凡联合主办的“2024 ÄKTA跨学科前沿论坛”于2024年12月12日在上海召开。 本次论坛汇聚了国内顶尖科学家，围绕创新药物研发、天然产物开发等多个领域展开深度交流与探讨，挖掘生命科学技术对跨学科发展所起到的核心赋能作用，以及其在推动领域前行过程中所展现的变革性与影响力。 开幕致辞 论坛在大会主席丁克教授与Cytiva中国总裁李蕾先生的致辞中正式拉开帷幕。两位分别从生命科学领域的全球视角出发，强调了多学科交叉在突破科学研究瓶颈中的重要性。 丁克教授 “近年来，随着生命科学研究的不断深入和技术的迅猛发展，多学科交叉已成为推动科学突破的关键动力。无论是蛋白质研究、结构生物学，还是药物开发与生物制剂生产，跨学科的创新思维正在重新定义我们的研究模式和未来方向。今天我们在这里进行经验分享、思想碰撞，希望能以此为契机，在跨学科合作的道路上携手前行，共同探索生命科学研究的更多可能性。” 李蕾先生 “Cytiva不仅是科研工作者的技术伙伴，更是跨学科协作和成果转化的重要推动者。未来，我们希望从用户的角度创造更多的机会，和各位科学家进行互动，共同讨论科学的话题，用科学的工具，解决科学的问题。与中国的科学家共同成长，帮助每一位科研工作者的科研发展迈向新的科研高峰。” 前沿科学报告 来自创新药物研发、天然产物开发、创新治疗方法等研究领域的重量级嘉宾，围绕跨学科热点展开了全面的讨论和分享。 丁克：基于临床需求的激酶药物化学研究 国家杰青、生命过程小分子调控全国重点实验室常务副主任丁克教授，详细介绍了药物化学的概念，报告了自己最新的科研成果和方向。他认为理解药物化学首先要从化学的视角去理解疾病的生物学内涵；更重要的是以化学的方法，从临床的需求出发，寻找能够解决疾病的新分子，这是当下对药学化学领域人的新要求。因此，基于这两个条件决定了这门学科的本质：从真正的尚未满足的临床需求出发，去寻找真正安全、有效且可及的功能性分子。 万谦：糖类天然药物制备关键技术 国家杰青、武汉大学药学院院长万谦教授，聚焦于复杂糖类天然产物的提取和高效制备技术。他详细阐述了团队在糖基化反应领域的创新，强调了糖类化合物在抗肿瘤、抗病毒等领域的潜在应用价值，展示了糖化学在药物研发中的广阔前景。 党永军：活性小分子的发现与机制研究 长江学者、重庆医科大学药学院院长党永军教授，认为从小分子角度进行机制研究充满了魅力，小分子的魅力在于可以解决很多生物学不能“理解”的工作：比如把两个分子粘到一起，或者链接两个蛋白，形成新的分子，这些应用在抗衰老、肿瘤、免疫抑制等领域都得到了应用和发展。 张翱：抗消化道肿瘤药物研究 国家杰青、上海交通大学药学院院长张翱教授，从中国肿瘤疾病谱的角度出发，为大家介绍了消化道肿瘤治疗的现状和难点。以胰腺癌治疗为例，不管是靶向药物还是免疫药物治疗效果都不佳；通过大规模胰腺癌病人的样本分析，从而找到胰腺癌有效的治疗靶点，从临床角度去解决现在临床的困境。 冯峰：Cytiva下游智能平台技术加速基础科研到药物开发 Cytiva ÄKTA资深产品专家冯峰博士，介绍了ÄKTA作为药物研发和生产的“黄金标准”，以高通量、高精度、合规性的特点，不仅提升纯化效率，还为药学研究和工艺表征验证提供了针对性的解决方案。 胡克平： 机体能量代谢三羧酸循环TCA蛋白质复合物新发现与心肌病发病机制研究 中国医学科学院药用植物研究所药理毒理研究中心主任胡克平研究员，分享其作为法玛西亚时代就开始使用ÄKTA的最早期用户，为大家分享了许多蛋白质复合物发现方面的最新科研成果。 张宏恺： 基于肿瘤和引流淋巴结微环境的研究合理设计溶瘤病毒 国家“四青”、南开大学生命科学学院张宏恺教授，重点讨论了如何基于肿瘤及其引流淋巴结的微环境特征，合理设计溶瘤病毒以提高其疗效。他还分享了团队在溶瘤病毒改造方面的最新成果，展示了其在增强抗肿瘤免疫反应中的潜力。 周璐：针对糖脂代谢酶的新药研究 长江学者、复旦大学药学院副院长周璐教授，聚焦糖脂代谢酶在代谢性疾病中的关键作用，探讨了针对这些酶的新药开发策略。他详细介绍了靶向糖脂代谢酶的小分子抑制剂的设计、合成及其在临床前研究中的表现，为代谢性疾病的治疗提供了新的思路。 罗成：如何加速新药开发的思考与实践 国家杰青、中国科学院上海药物研究所罗成研究员，分享了从植物、海洋生物和微生物中提取和分离具有潜在药用价值的天然化合物，并且创建了一个涵盖多种结构类型的高质量天然产物分子库，为高通量筛选和生物活性探索提供了重要资源，也为新药研发提供了现实可行的路径。通过将基础研究与产业需求相结合，推动天然产物的研发和成药路径的实现。 王程远：致病耐药菌新型转录调控机制解析 国家优青、中国科学院上海免疫与感染研究所王程远研究员，解析了耐药致病菌的转录调控机制，揭示细菌如何通过基因表达调控来适应抗生素压力。他的研究为开发新的抗菌策略提供了理论基础，有望为克服当前抗生素耐药带来新的机会。 李思蜀：前沿层析填料-助力生命科学研究与转化 Cytiva填料产品高级产品专家李思蜀，介绍了Cytiva在层析填料领域的最新技术进展，展示了新型填料在蛋白质纯化和生物制药中的应用优势。她强调高性能层析填料在提高纯化效率、产品质量和降低成本方面的关键作用，助力生命科学研究的成果转化。 ÄKTA Club 发布 在大家的共同见证下，Cytiva隆重推出的ÄKTA Club正式上线！它将以“连接、赋能、共创”为使命，作为专为科学家打造的层析纯化专业社区，为全球科研人员提供一个专属的交流、合作与成长平台。这不仅是Cytiva赋能科研的全新尝试，更是连接科研生态的战略举措。 发布现场(滑动查看) 讨论交流 讨论集锦(滑动查看) 本次论坛从微观分子机制到宏观疾病治疗，从基础研究创新到技术成果转化，全方位展示生命科学前沿动态与发展趋向。见证理论创新与技术突破，看到科研成果向应用迈进的坚实步伐，深感跨学科合作在攻克复杂难题中的强大力量，为日后跨学科交流奠定了基础。 愿今日所学所思，在未来科研征程中化为创新源泉、实践动力。携手共进，为生命科学发展、人类健康福祉奋勇拼搏。期待下次相聚，共攀科研高峰、续写辉煌篇章！ 一审| 黄佳 二审| 李芳晨 三审| 李静芝

The partnership between Roche and Poseida began in 2022, focusing on the development of off-the-shelf CAR-T cell therapies. Credit: metamorworks/Shutterstock. Roche has signed an agreement to acquire Poseida Therapeutics in a $1.5bn deal. The transaction includes Poseida’s clinical and pre-clinical CAR-T therapies and manufacturing capabilities. The acquisition will also integrate Poseida’s employees into Roche’s Pharmaceuticals Division. Roche will begin a tender offer to acquire complete outstanding Poseida common stock shares for $9 per share in cash at closing, along with a non-tradeable contingent value right (CVR) for potential milestone payments of up to an aggregate of $4 per share in cash. This represents almost $1bn in total equity value at closing. The merger agreement has received unanimous approval from the boards of both Roche and Poseida. Following the tender offer, Roche will acquire all remaining shares at the same price through a second-step merger. The transaction will conclude in the first quarter (Q1) of 2025, subject to customary closing conditions, including the tender of a majority of Poseida’s outstanding shares. Roche chief medical officer and Product Development head Levi Garraway stated: “This exciting acquisition will allow us to drive further progress in allogeneic cell therapy while leveraging the successful existing partnership with Poseida. “We are very encouraged by the early clinical data, and this acquisition builds on our joint progress to catalyse the development of potentially first and best-in-class cell therapies in oncology, immunology and neurology.” The partnership between Roche and Poseida began in 2022, focusing on the development of off-the-shelf CAR-T cell therapies. Roche is set to gain access to Poseida’s good manufacturing practices (GMP) manufacturing capabilities and a suite of research and development assets, including P-MUC1C-ALLO1, an allogeneic CAR-T programme in Phase I for solid tumours, and various genomic medicine pre-clinical candidates. Citi is serving as the exclusive financial advisor to Roche, with Sidley Austin providing legal counsel. Poseida is advised by Centerview Partners, with Cooley acting as legal counsel. In September 2022, Roche signed an agreement for the acquisition of Good Therapeutics. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva . Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content. Free Whitepaper Cell and gene therapies: Pipe dream to pipeline The cell and gene industry is gaining momentum, with a new wave of therapies promising to transform the way doctors treat, and even cure, disease. In this report, Cytiva and GlobalData have collaborated to explore the rise of the cell and gene therapy industries, the current state of the market, present and future opportunities for advancement, and the challenges that lie ahead. Thank you. You will receive an email shortly. Please check your inbox to download the Whitepaper. By Cytiva Thematic By downloading this Whitepaper, you acknowledge that GlobalData may share your information with Cytiva Thematic and that your personal data will be used as described in their Privacy Policy